Budget Impact Analysis of Anticoagulation Clinics in Patients with Atrial Fibrillation Under Chronic Therapy with Oral Anticoagulants

Overview

Journal J Prim Care Community Health

Publisher Sage Publications

Specialty Health Services

Date 2021 Mar 15

PMID 33719701

Citations 2

Authors

William Uribe-Arango

Juan Manuel Reyes Sanchez

Natalia Castano Gamboa

Affiliations

Soon will be listed here.

Abstract

Objectives: To assess budget impact of the implementation of an anticoagulation clinic (AC) compared to usual care (UC), in patients with non-valvular atrial fibrillation (NVAF).

Method: A decision tree was designed to analyze the cost and events rates over a 1-year horizon. The patients were distributed according to treatment, 30% Direct Oral Anticoagulant (DOAC) regimens and the rest to warfarin. The thromboembolism and bleeding were derived from observational studies which demonstrated that ACs had important impact in reducing the frequency of these events compared with UC, due to higher adherence with DOACs and proportion of time in therapeutic range (TTR) with warfarin. Costs were derived from the transactional platform of Colombian government, healthcare authority reimbursement and published studies. The values were expressed in American dollars (USD). The exchanged rate used was COP $3.693 per dollar.

Results: During 1 year of follow-up, in a cohort of 228 patients there were estimated 48 bleedings, 6 thromboembolisms in AC group versus 84 bleedings, and 12 thromboembolisms events in patients receiving UC. Total costs related to AC were $126 522 compared with $141 514 in UC. The AC had an important reduction in the cost of clinical events versus UC ($52 085 vs $110 749) despite a higher cost of care facilities ($74 436 vs $30 765). A sensibility analysis suggested that in the 83% of estimations, the AC produced savings varied between $27 078 and $135 391.

Conclusions: This study demonstrated that AC compared with UC, produced an important savings in the oral anticoagulation therapy for patients with NVAF.

Citing Articles

The budget impact of implementing atrial fibrillation-screening in European countries.

Eklund M, Bernfort L, Appelberg K, Engler D, Schnabel R, Martinez C Eur Heart J Suppl. 2024; 26(Suppl 4):iv19-iv32.

PMID: 39099577 PMC: 11292408. DOI: 10.1093/eurheartjsupp/suae076.

Geller A, Shehab N, Lovegrove M, Weidle N, Budnitz D Thromb Res. 2023; 225:110-115.

PMID: 37062120 PMC: 10870325. DOI: 10.1016/j.thromres.2023.03.010.

References

Lafata J, Martin S, Kaatz S, Ward R . The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med. 2000; 15(1):31-7. PMC: 1495325. DOI: 10.1046/j.1525-1497.2000.01239.x. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice.... Circulation. 2011; 123(10):e269-367. DOI: 10.1161/CIR.0b013e318214876d. View

Kernan W, Ovbiagele B, Black H, Bravata D, Chimowitz M, Ezekowitz M . Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7):2160-236. DOI: 10.1161/STR.0000000000000024. View

Chiquette E, Amato M, Bussey H . Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998; 158(15):1641-7. DOI: 10.1001/archinte.158.15.1641. View

Sylvester K, Ting C, Lewin A, Collins P, Fanikos J, Goldhaber S . Expanding anticoagulation management services to include direct oral anticoagulants. J Thromb Thrombolysis. 2017; 45(2):274-280. DOI: 10.1007/s11239-017-1602-1. View

Shore S, Ho P, Lambert-Kerzner A, Glorioso T, Carey E, Cunningham F . Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015; 313(14):1443-50. DOI: 10.1001/jama.2015.2761. View

Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D . Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007; 11(38):iii-iv, ix-66. DOI: 10.3310/hta11380. View

Matchar D, Samsa G, Cohen S, Oddone E, Jurgelski A . Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002; 113(1):42-51. DOI: 10.1016/s0002-9343(02)01131-2. View

Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad J . Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017; 24(14):1555-1566. PMC: 5598874. DOI: 10.1177/2047487317715769. View

10.

Kim D, Yang P, Jang E, Yu H, Kim T, Uhm J . The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Europace. 2019; 22(4):547-557. DOI: 10.1093/europace/euz273. View

11.

Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R . Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2011; 379(9813):322-34. DOI: 10.1016/S0140-6736(11)61294-4. View

12.

Parry D, Fitzmaurice D, Raftery J . Anticoagulation management in primary care: a trial-based economic evaluation. Br J Haematol. 2000; 111(2):530-3. DOI: 10.1046/j.1365-2141.2000.02360.x. View

13.

Witt D, Sadler M, Shanahan R, Mazzoli G, Tillman D . Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005; 127(5):1515-22. DOI: 10.1378/chest.127.5.1515. View

14.

Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P . Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2009; 1(2):84-91. DOI: 10.1161/CIRCOUTCOMES.108.796185. View

15.

Barnes G, Lucas E, Alexander G, Goldberger Z . National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015; 128(12):1300-5.e2. PMC: 4658248. DOI: 10.1016/j.amjmed.2015.05.044. View

16.

Barnes G, Kline-Rogers E . Engaging with quality improvement in anticoagulation management. J Thromb Thrombolysis. 2015; 39(3):403-9. PMC: 4822820. DOI: 10.1007/s11239-015-1184-8. View

17.

Emren S, Senoz O, Bilgin M, Beton O, Aslan A, Taskin U . Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2017; 24(3):525-531. PMC: 6714660. DOI: 10.1177/1076029617693940. View

18.

Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L . Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007; 23(2):83-91. DOI: 10.1007/s11239-006-9022-7. View

19.

Mohammad I, Korkis B, Garwood C . Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics. Pharmacotherapy. 2017; 37(10):1284-1297. DOI: 10.1002/phar.1991. View